Last updated 2 months ago

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

175 patients around the world
Available in United States, Brazil
The study is comprised of a Baseline Visit and 2 Follow-up Periods. For Follow-up Periods 1 and 2, which includes Baseline through Year 5 visits, assessments will be performed at the Investigational site. For the first 2 years (Follow-up Period 1), visits will occur every 6 months. For Years 3 to 5 (Follow-up Period 2) follow-up visits will be conducted annually. All patients will enter the study at the baseline visit and continue for 5 years.
Novartis Pharmaceuticals
175Patients around the world

This study is for people with

Rare diseases
Spinal muscular atrophy

Requirements for the patient

To 100 Years
All Gender

Medical requirements

Participated in an OAV101 clinical trial.
Written informed consent must be obtained before any assessment is performed.
Patient/Parent/legal guardian willing and able to comply with study procedures.
There are no exclusion criteria for this study.
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy